Antinükleer antikor-hep-2 (ANA) testinin tarama titresi için pozitiflik değerinin belirlenmesi.

Objective: It is important to choose the correct screening titer in immunoflourescent assay for ANA. Recently, 1:160 titer is used worldwide, particularly after the suggestion of CDC (Centers for Disease Control and Prevention) and WHO (World Health Organisation). In our country, 1:100 is the mostly accepted titer for screening as a cutoff point. In this study, our aim was to check the ideal screening titer for Turkish society and investigate the convenience of suggested 1:160 screening titer for our country. Methods: Between January- February 2015, a total of 400 patients (healthy blood donors and patients with autoimmune rheumatic diseases- has been diagnosed or followed) were included in the study. Serum samples taken from donors and patients worked ANA test with two different commercial (Aesku and Euroimmun) kits by 1:100 and 1:160 screening titers. Microscobic evaluation determinated by blind and automated system (Helios). The serum samples detected positive by 1:100 and 1:160 titers worked. In the end sensivity and specificity of the ANA test was figured out. Also cut-off values of the test was figured out by ROC curve analyse. Results: In healthy group the frequency of positivity is 8%, whereas in patients group it is 92%. In healthy group distribution of ANA titer positivity is: in 1:100 titer 44%, in 1: 160 -31%, in 1: 320 -19% and in 1: 640 -6%. In healthy group in 1:160 distribution of ANA patern is: dense fine speck (dfs 70) 56%, speck 25%, nucleolar 12,5%, centromere 6.5%. In patients' group distribution of ANA titer positivity is: in 1:100-1%, in 1:160-3%, in 1:320-26%, in 1:640 25%, in 1:280-34%, in 1:2560-8% and in 1:5120-3%. In patients group in 1:160 distribution of ANA patern is: speck 55%, homogeneous 24%, nucleolar 11%, centromere 5%, nuclear dots 3% and nuclear membrane 2%. Conclusion: In our study, the ideal screening titer of 1:160 for ANA test was confirmed. The screening titer of 1:160, as proposed by CDC and WHO, is found confident to use in the laboratories in Turkey. [ABSTRACT FROM AUTHOR]